Top Page
CSPC Pharmaceutical Group
(OTC:1093)
CSPC Pharmaceutical Group (1093) vs. iShares MSCI Hong Kong ETF (EWH)
CSPC Pharmaceutical Group Business Overview & Revenue Model
CSPC Pharmaceutical Group Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 30.87B | 34.60B | 31.59B | 33.59B | 28.03B |
| Gross Profit | 21.60B | 24.40B | 22.73B | 25.47B | 21.00B |
| EBITDA | 6.96B | 8.53B | 8.66B | 9.28B | 8.09B |
| Net Income | 4.61B | 5.87B | 6.09B | 5.61B | 5.16B |
Balance Sheet | |||||
| Total Assets | 44.39B | 46.28B | 41.77B | 42.50B | 35.65B |
| Cash, Cash Equivalents and Short-Term Investments | 8.60B | 13.09B | 13.68B | 13.87B | 10.47B |
| Total Debt | 507.33M | 706.90M | 659.28M | 115.04M | 375.51M |
| Total Liabilities | 10.52B | 11.26B | 11.07B | 9.37B | 8.28B |
| Stockholders Equity | 32.26B | 33.20B | 29.77B | 31.79B | 26.48B |
Cash Flow | |||||
| Free Cash Flow | 1.86B | 2.29B | 5.32B | 3.74B | 5.91B |
| Operating Cash Flow | 4.53B | 4.18B | 7.63B | 4.64B | 6.74B |
| Investing Cash Flow | -3.86B | 607.27M | -6.80B | -637.33M | -2.13B |
| Financing Cash Flow | -5.25B | -2.30B | -1.90B | -2.20B | -1.47B |
CSPC Pharmaceutical Group Technical Analysis
CSPC Pharmaceutical Group Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | HK$88.89B | 19.33 | 13.20% | 2.59% | -9.60% | -27.18% | |
60 Neutral | HK$15.14B | 5.55 | -7.43% | 4.78% | 11.72% | -20.69% | |
| $12.07B | 49.57 | 6.14% | 1.52% | ― | ― | ||
| $16.27B | ― | -0.72% | ― | ― | ― | ||
| $7.41B | 6.95 | 9.19% | 4.30% | ― | ― | ||
| $13.04B | 27.99 | 8.17% | ― | ― | ― | ||
73 Outperform | HK$173.06B | 36.41 | 16.09% | 1.18% | 19.29% | 31.35% |
CSPC Pharmaceutical Group Corporate Events
CSPC Pharmaceutical Group Limited has announced a change in the composition of its Nomination Committee with the appointment of Ms. LI Quan as a member, effective June 27, 2025. This strategic move is expected to enhance the company’s governance structure and potentially influence its decision-making processes, reflecting its commitment to strengthening leadership and oversight.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$6.80 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group Limited has announced the composition of its board of directors, including both executive and independent non-executive directors. This announcement provides clarity on the roles and functions of the board members, which is crucial for stakeholders to understand the company’s governance structure.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$6.80 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group Limited has updated the terms of reference for its Nomination Committee, which is responsible for reviewing the board’s structure and diversity, identifying and recommending director candidates, and assessing the independence of non-executive directors. This move aims to enhance the company’s governance and ensure alignment with its corporate strategy, potentially impacting its operational efficiency and stakeholder confidence.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$6.80 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group Limited has announced the signing of new lease agreements as the previous ones are set to expire in June 2025. The new agreements involve several subsidiaries of the company and are structured as connected transactions under Hong Kong’s Listing Rules. These agreements, which extend the leases for various premises for three years, are subject to certain reporting and announcement requirements, reflecting the company’s ongoing operational adjustments and compliance with regulatory standards.
The most recent analyst rating on (HK:1093) stock is a Hold with a HK$6.50 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group has announced that its Meloxicam Injection (Ⅲ), a nanocrystal product for intravenous administration, has received drug registration approval in China. This approval marks a significant advancement in the company’s product portfolio, enhancing its position in the analgesic treatment market and demonstrating a breakthrough in nanomedicine research.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$6.80 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group has entered into a strategic research collaboration with AstraZeneca to discover and develop novel oral small molecule candidates using CSPC’s AI-driven drug discovery platform. This agreement allows AstraZeneca to potentially license these candidates for global development and commercialization, with CSPC receiving significant upfront and milestone payments, as well as potential royalties, indicating a substantial impact on CSPC’s operations and industry positioning.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$6.80 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group has received approval from the U.S. FDA to conduct clinical trials for its new antibody-drug conjugate, SYS6040, targeting advanced solid tumors. This development signifies a significant step in the company’s expansion into the U.S. market, potentially enhancing its competitive position in oncology therapeutics.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$6.80 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group Limited has announced that its Cobamamide Capsules have received drug registration approval from the National Medical Products Administration of China. This approval enhances the company’s product portfolio in the therapeutic areas of hematology and neurology, potentially strengthening its market position and offering new treatment options for various types of anemia and nerve-related conditions.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$6.21 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group announced that its drug JMT101 has been granted Breakthrough Therapy Designation in China for treating advanced colorectal cancer. This designation, based on promising phase II clinical trial results, highlights JMT101’s potential to improve treatment outcomes for patients who have failed standard therapies, positioning it as a potential new standard for later-line colorectal cancer treatment.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$6.80 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group Limited announced the successful passing of all resolutions at its Annual General Meeting held on May 30, 2025. Key resolutions included the approval of financial statements for 2024, the declaration of a final dividend, re-election of directors, and the granting of mandates for share buy-backs and issuance. These resolutions reflect the company’s strategic direction and commitment to shareholder value, potentially impacting its market positioning and stakeholder confidence.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$6.21 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group has announced ongoing negotiations for three potential license and collaboration transactions aimed at the development and commercialization of its pharmaceutical products, including EGFR-ADC. These transactions could bring in approximately US$5 billion in aggregate payments, with one deal expected to be finalized by June 2025, potentially impacting the company’s market positioning and financial outlook.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$6.21 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group reported a significant decline in its quarterly financial results for the three months ended March 31, 2025. The company’s total revenue decreased by 21.9% compared to the previous year, primarily due to a 27.3% drop in finished drug sales, impacted by industry policies such as centralized procurement and drug price adjustments. Despite this, the bulk products segment saw a 14.6% revenue increase, driven by higher demand and prices for vitamin C products. The company has been actively promoting product internationalization and out-licensing initiatives, which have contributed to a rise in license fee income, partially offsetting the decline in drug sales and providing potential future growth.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$6.21 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group Limited has announced that its bispecific fusion protein drug, JMT106, has received approval from the National Medical Products Administration of China to conduct clinical trials for advanced solid tumors. This approval, alongside a similar approval from the U.S. FDA, highlights the drug’s potential in treating various cancers, including hepatocellular carcinoma and ovarian cancer, and signifies a promising step in the company’s clinical development efforts.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$10.26 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group announced that its drug CPO301 has received the third Fast Track designation from the U.S. FDA for treating advanced non-small cell lung cancer (NSCLC) without EGFR mutations. This designation highlights the drug’s promising clinical efficacy and is expected to expedite its development and registration globally, potentially enhancing CSPC’s position in the oncology market.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$10.26 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group Limited has announced a board meeting scheduled for May 29, 2025, to approve the unaudited first quarterly results for the period ending March 31, 2025. This meeting is significant as it will provide insights into the company’s financial performance for the first quarter of 2025, which could impact its market positioning and stakeholder confidence.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$10.26 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group Limited has entered into an exclusive license agreement with Cipla USA, Inc. for the commercialization of its Irinotecan Liposome Injection in the United States. This agreement includes an upfront payment of $15 million to CSPC, with potential milestone payments and royalties based on sales. This strategic partnership is expected to enhance CSPC’s market presence in the U.S. and potentially increase its revenue through milestone and royalty payments.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$10.26 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group announced that its Vonoprazan Fumarate Tablets have received drug registration approval from China’s National Medical Products Administration. This approval enhances the company’s product portfolio in digestive system therapies, offering a novel treatment option with advantages over conventional proton pump inhibitors, potentially strengthening its market position.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$10.26 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group Limited has announced that its SYH2046 Tablets have received approval from the U.S. FDA to conduct clinical trials in the United States. This first-in-class small molecule drug, which targets heart failure after acute myocardial infarction, has shown promising preclinical results in improving cardiac function and safety. The approval marks a significant step in the company’s efforts to bring novel treatments to market, potentially enhancing its position in the pharmaceutical industry and offering new hope for patients with heart conditions.
CSPC Pharmaceutical Group Limited has announced that its drug JMT202, a recombinant fully human anti-βKlotho monoclonal antibody, has received approval from the U.S. FDA to conduct clinical trials in the United States. This development marks a significant step for the company as the drug, which targets metabolism-related diseases, has already shown promising results in preclinical studies, potentially enhancing CSPC’s market position in the treatment of hypertriglyceridemia and related conditions.
CSPC Pharmaceutical Group announced that its pivotal Phase II/III clinical study of KN026, a recombinant humanised anti-HER2 bispecific antibody, met the primary endpoint of progression-free survival with statistical significance. This development, particularly for patients with HER2-positive gastric or gastroesophageal junction adenocarcinoma, highlights KN026’s potential to improve treatment outcomes and reinforces CSPC’s position in the oncology drug market.
CSPC Pharmaceutical Group Limited has announced its upcoming annual general meeting scheduled for May 30, 2025, where key agenda items include the approval of financial statements, declaration of a final dividend, re-election of directors, and re-appointment of auditors. Additionally, the company seeks shareholder approval for a share buyback program, allowing the directors to repurchase up to 10% of the company’s issued shares, which could impact shareholder value and market perception.
CSPC Pharmaceutical Group Limited announced that its independently developed drug, SYH2068 Injection, has received approval from China’s National Medical Products Administration to conduct clinical trials. This siRNA drug targets lipoprotein(a) to treat hyperlipoproteinemia and potentially prevent atherosclerotic cardiovascular disease. Preclinical studies have shown the drug’s superior pharmacological activity and long-lasting effects, indicating promising clinical development value.
CSPC Innovation Pharmaceutical Co., Ltd., a subsidiary of CSPC Pharmaceutical Group, has released its unaudited financial results for the first quarter of 2025, showing a decrease in revenue and net profit compared to the previous year. Despite the decline in financial performance, the company managed to improve its net cash flow from operating activities significantly, indicating potential operational adjustments or efficiencies.
CSPC Pharmaceutical Group has announced that its subsidiary, Shanghai JMT-BIO Technology Co., Ltd., has received approval from the U.S. FDA to conduct clinical trials for its antibody drug JMT203 in the United States. This drug targets cancer cachexia, a condition with no current GDF15 or GFRAL-targeted treatments available globally. The approval marks a significant step in CSPC’s efforts to provide an effective treatment for cancer cachexia, potentially improving the quality of life for tumor patients and enhancing the company’s position in the pharmaceutical industry.
CSPC Pharmaceutical Group has announced that its Prusogliptin and Metformin Extended-Release Tablets have received approval from China’s National Medical Products Administration to commence clinical trials. This product is the first fixed-dose combination of prusogliptin and metformin hydrochloride approved for such trials, aimed at treating adult patients with type 2 diabetes mellitus who have inadequate control with metformin alone. The approval marks a significant step in CSPC’s clinical development, offering a promising safety and tolerability profile compared to existing monotherapy options.
CSPC Pharmaceutical Group has announced that its product, Oseltamivir Phosphate for Suspension, has received drug registration approval from China’s National Medical Products Administration. This approval enhances the company’s product portfolio in the anti-infective therapeutic area, potentially strengthening its market position and offering new treatment options for influenza A and B.
CSPC Pharmaceutical Group has announced that its investigational new drug, SYS6041, an antibody-drug conjugate, has received approval from the U.S. FDA to conduct clinical trials for advanced solid tumors in the United States. This development follows approval from China’s National Medical Products Administration and highlights the product’s promising anti-tumor effects demonstrated in preclinical studies, potentially enhancing CSPC’s position in the oncology market.
CSPC Pharmaceutical Group Limited has received approval from China’s National Medical Products Administration to conduct clinical trials for its new SYH2046 Tablets. This first-in-class small molecule drug, designed to treat heart failure following acute myocardial infarction, shows promise due to its novel mechanism of action and potential to improve cardiac function and patient outcomes compared to conventional treatments.
CSPC Pharmaceutical Group Limited announced that its new Class I bi-functional fusion protein drug, JMT108, has received approval from the U.S. FDA to conduct clinical trials in the United States. This approval, alongside prior approval in China, positions the company to advance its research on the drug’s efficacy against advanced malignant tumors, potentially enhancing its market positioning and offering promising implications for stakeholders.
CSPC Pharmaceutical Group Limited announced a final dividend of HKD 0.1 per share for the year ending December 31, 2024. This announcement reflects the company’s stable financial performance and commitment to returning value to its shareholders. The dividend will be paid on July 18, 2025, following shareholder approval on May 30, 2025. This move is likely to reinforce CSPC’s market position and enhance investor confidence.
CSPC Pharmaceutical Group reported a decline in its financial performance for the year 2024, with total revenue dropping by 7.8% and profit attributable to shareholders decreasing by 26.3%. The company completed significant share buy-backs and announced further buy-back plans, reflecting strategic financial management amidst industry challenges and opportunities. The Chinese pharmaceutical industry is experiencing transformative changes driven by policy reforms and innovation incentives, which CSPC is poised to leverage for future growth.